SCHEMBL24019646

SCHEMBL24019646

CCC(=O)c1cc2cccc(OC)c2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.62
HRH4 Q9H3N8 2/20 0.57
FLT3 P36888 2/20 0.57
MTNR1A P48039 2/20 0.55
MTNR1B P49286 2/20 0.55
DRD2 P14416 1/20 0.49
DRD3 P35462 1/20 0.49
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
KDM4E B2RXH2 4/20 0.43
HPGD P15428 3/20 0.43
TP53 P04637 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324813 0.83 FLT3 (0.61) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL1144995 0.83 HPGD (0.62) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL3276252 0.83 KDM4E (0.57) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL5355599 0.82 GLA (0.68) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL17321408 0.79 FLT3 (0.57) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL24740173 0.79 HRH4 (0.56) IDO1HRH4FLT3DRD2DRD3
SCHEMBL10508317 0.79 HRH4 (0.51) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL6860186 0.77 FLT3 (0.77) HRH4FLT3
SCHEMBL10507997 0.77 HRH4 (0.52) IDO1HRH4FLT3MTNR1AMTNR1B
SCHEMBL24019713 0.77 IDO1 (0.64) IDO1HRH4FLT3MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL IDO1 1633/4885HRH4 4013/4885FLT3 2640/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV IDO1 1859/4885HRH4 4259/4885FLT3 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.